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Abstract
Objective: Higher circulating levels of tissue inhibitor of matrix metalloproteinases (TIMP)-1 at the time of severe sepsis
diagnosis have been reported in nonsurviving than in surviving patients. However, the following questions remain
unanswered: 1) Does TIMP-1/MMP-9 ratio differ throughout the first week of intensive care between surviving and non-
surviving patients? 2) Is there an association between TIMP-1/MMP-9 ratio and sepsis severity and mortality during such
period? 3) Could TIMP-1/MMP-9 ratio during the first week be used as an early biomarker of sepsis outcome? 4) Is there an
association between TIMP-1/MMP-9 ratio and coagulation state and circulating cytokine levels during the first week of
intensive care in these patients? The present study sought to answer these questions.
Methods: Multicenter, observational and prospective study carried out in six Spanish Intensive Care Units (ICUs) of 295
patients with severe sepsis. Were measured circulating levels of TIMP-1, MMP-9, tumour necrosis factor (TNF)-alpha,
interleukin (IL)-10 and plasminogen activator inhibitor (PAI)-1 at day 1, 4 and 8. End-point was 30-day mortality.
Results: We found higher TIMP-1/MMP-9 ratio during the first week in non-surviving (n = 98) than in surviving patients
(n = 197) (p,0.01). Logistic regression analyses showed that TIMP-1/MMP-9 ratio at days 1, 4 and 8 was associated with
mortality. Receiver operating characteristic (ROC) curves showed that TIMP-1/MMP-9 ratio at days 1, 4 and 8 could predict
mortality. There was an association between TIMP-1/MMP-9 ratio and TNF-alpha, IL-10, PAI-1 and lactic acid levels, SOFA
score and platelet count at days 1, 4 and 8.
Conclusions: The novel findings of our study were that non-surviving septic patients showed persistently higher TIMP-1/
MMP-9 ratio than survivors ones during the first week, which was associated with severity, coagulation state, circulating
cytokine levels and mortality; thus representing a new biomarker of sepsis outcome.
Citation: Lorente L, Martı´n MM, Sole´-Viola´n J, Blanquer J, Labarta L, et al. (2014) Association of Sepsis-Related Mortality with Early Increase of TIMP-1/MMP-9
Ratio. PLoS ONE 9(4): e94318. doi:10.1371/journal.pone.0094318
Editor: Jose Carlos Alves-Filho, University of Sa˜o Paulo, Brazil
Received November 14, 2013; Accepted March 14, 2014; Published April 11, 2014
Copyright:  2014 Lorente et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported, in part, by grants from Instituto de Salud Carlos III (FIS-PI-10-01572, I3SNS-INT-11-063 and I3SNS-INT-12-087) (Madrid, Spain)
and co-financed by Fondo Europeo de Desarrollo Regional (FEDER), CIMA (University of Navarra, Pamplona, Spain), and Sociedad Espan˜ola de Trombosis y
Hemostasia (SETH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lorentemartin@msn.com
Introduction
Sepsis represents a systemic response of the immune system to
infection leading to high mortality and costs [1,2]. Matrix
metalloproteinases (MMPs) are a family of zinc-containing
endoproteinases that are implicated in degradation and remodel-
ling of the extracellular matrix (ECM) [3]; and also in proteolysis
of intracellular protein [4–6], and are involved in innate immune
defence and apoptosis. The regulation of MMP activity is complex
and occurs at several levels [7], such as transcriptional (MMP gene
expression in cells) which is modified by TNF-a, interleukin-1b
and transforming growth factor (TGF)-b; post- transcriptional
(stability of MMP transcripts in cells) which is influenced by
glucocorticoids and TGF-b; translational (release of MMP from
cells) which is regulated by plasmin and thrombin; and post-
translational (activation of MMPs after the release) which is
affected by oxidative stress, nitrosative stress, phosphorylation [8],
proteolysis and tissue inhibitors of matrix metalloproteinases
(TIMPs). MMPs and TIMPs help modulate inflammatory [9]
and prothrombotic responses [10,11].
Previous clinical studies including our own have shown higher
circulating levels of MMP-9 and TIMP-1 in septic patients than in
controls [12–22], and higher levels of TIMP-1 [15,19,20,23] at the
time of severe sepsis diagnosis in non-surviving than in surviving
patients. In addition, an association between circulating TIMP-1
and plasminogen activator inhibitor (PAI)-1 levels in septic
patients at severe sepsis diagnosis has been reported [23].
However, the following questions remain unanswered: 1) Does
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Table 1. Baseline clinical and biochemical characteristics of survivor and non-survivor patients.
Survivors (n=197) Non-survivors (n =98) P
Male sex– n (%) 65 (23.0) 35 (35.7) 0.70
Age - median years (percentile 25–75) 59 (47–69) 64 (55–74) 0.004
Diabetes Mellitus – n (%) 49 (24.9) 38 (38.8) 0.01
COPD - n (%) 26 (13.2) 13 (13.3) 0.99
Ischemic heart disease - n (%) 21(11.0) 10 (10.3) 0.99
Site of infection 0.67
Respiratory - n (%) 111 (56.3) 58 (59.2)
Abdominal - n (%) 55 (27.9) 25 (25.5)
Urinary - n (%) 11 (5.6) 4 (4.1)
Skin - n (%) 9 (4.6) 4 (4.1)
Endocarditis - n (%) 6 (3.0) 5 (5.1)
Arthritis - n (%) 0 1 (1.0)
CNS- n (%) 5 (2.5) 1 (1.0)
Microorganism responsibles
Unknown- n (%) 97 (49.2) 51 (52.0) 0.71
Gram-positive- n (%) 50 (25.4) 25 (25.5) 0.99
Gram-negative- n (%) 50 (25.4) 21 (21.4) 0.47
Fungii- n (%) 4 (2.0) 4 (4.1) 0.45
Anaerobe - n (%) 2 (1.0) 1 (1.0) 0.99
Bloodstream infection - n (%) 30 (15.2) 17 (17.3) 0.74
Empiric antimicrobial treatment adequate 0.68
Unknown due to negative cultures - n (%) 97 (49.2) 52 (53.1)
Unknown due to diagnosis by antigenuria - n (%) 14 (7.1) 4 (4.1)
Adequate - n (%) 82 (41.6) 39 (39.8)
Inadequate - n (%) 4 (2.0) 3 (3.1)
Treatment with betalactamic more aminoglycoside - n (%) 43 (22.1) 24 (24.5) 0.66
Treatment with betalactamic more quinolone - n (%) 101 (51.8) 51 (52.0) 0.99
Pa02/FI02 ratio - median (percentile 25–75) 180 (122–270) 168 (101–240) 0.12
Creatinine (mg/dl) - median (percentile 25–75) 1.30 (0.84–2.10) 1.60 (1.00–2.90) 0.009
Bilirubin (mg/dl) - median (percentile 25–75) 0.90 (0.50–1.47) 0.90 (0.50–2.30) 0.41
Leukocytes - median*103/mm3 (percentile 25–75) 14.7 (9.2–20.0) 15.0 (7.1–20.6) 0.85
Lactic acid - median mmol/L (percentile 25–75) 2.00 (1.10–3.40) 3.55 (1.60–6.00) ,0.001
Platelets - median*103/mm3 (percentile 25–75) 197 (131–273) 132 (63–222) ,0.001
INR - median (percentile 25–75) 1.27 (1.10–1.51) 1.42 (1.14–1.89) 0.008
aPTT - median seconds (percentile 25–75) 32 (28–39) 36 (29–45) 0.008
SOFA score - median (percentile 25–75) 9 (7–11) 11 (9–14) ,0.001
APACHE-II score - median (percentile 25–75) 19 (15–23) 24 (19–29) ,0.001
TIMP-1– median ng/ml (percentile 25–75) 548 (372–732) 750 (479–1020) ,0.001
MMP-9 - median ng/ml (percentile 25–75) 760 (359–1208) 533 (231–952) 0.003
TIMP-1/MMP-9 ratio (percentile 25–75) 0.71 (0.40–1.54) 1.26 (0.64–3.86) 0.003
TNF-alpha - median pg/ml (percentile 25–75) 30 (20–50) 36 (18–74) 0.24
IL-10 - median pg/ml (percentile 25–75) 11 (6–37) 38 (9–119) ,0.001
PAI-1 - median ng/ml (percentile 25–75) 36 (21–62) 58 (33–84) ,0.001
COPD = chronic obstructive pulmonary disease; CNS = Central Nervous System; PaO2/FIO2 = pressure of arterial oxygen/fraction inspired oxygen; INR = international
normalized ratio; aPTT = activated partial thromboplastin time; SOFA = Sepsis-related Organ Failure Assessment score; APACHE II = Acute Physiology and Chronic
Health Evaluation; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of matrix metalloproteinase; TNF = tumour necrosis factor; IL = Interleukin; PAI =
Plasminogen activator inhibitor.
doi:10.1371/journal.pone.0094318.t001
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TIMP-1/MMP-9 ratio differ throughout the first week of intensive
care between surviving and non-surviving septic patients? 2) Is
there an association between TIMP- 1/MMP-9 ratio and sepsis
severity during this period? 3) Is there an association between
TIMP-1/MMP-9 ratio during the first week and sepsis mortality?
4) Could TIMP- 1/MMP-9 ratio be used as an early biomarker of
sepsis outcome? 5) Is there an association between TIMP-1/
MMP-9 ratio and coagulation state during the first week of
intensive care in these patients? 6) Is there an association between
TIMP-1/MMP-9 ratio and circulating cytokine levels during the
first week of intensive care in septic patients? The present study
sought to answer these questions. We focus on the determination
of the TIMP-1/MMP-9 ratio because in previous studies we
assessed serum TIMP-1 and MMP-9 levels [19,23], and because
MMP-9 is inhibited by TIMP-1.
Methods
Design and Subjects
A prospective, multicenter observational study was carried out
in six Spanish intensive care units (ICUs). The Institutional Ethic
Review Boards of the six hospitals approved this study: Hospital
Universitario de Canarias (La Laguna. Santa Cruz de Tenerife.
Spain), Hospital Universitario Nuestra Sen˜ora de Candelaria
(Santa Cruz de Tenerife. Spain), Hospital Universitario Dr.
Negrı´n (Las Palmas de Gran Canaria. Spain), Hospital Clı´nico
Universitario de Valencia (Valencia. Spain), Hospital San Jorge
(Huesca. Spain) and Hospital Insular (Las Palmas de Gran
Canaria. Spain). Written informed consent from the patients or
from their family members was obtained.
Patients admitted to the ICU of the participating hospitals and
meeting the criteria for severe sepsis were included in the present
study. The diagnosis of severe sepsis was established according to
the International Sepsis Definitions Conference [24]. Exclusion
criteria were: age ,18 years, pregnancy, lactation, human
immunodeficiency virus (HIV), white blood cell count ,103/
mm3, solid or hematological tumors or immunosuppressive,
steroid or radiation therapy.
Variables recorded
The following variables were recorded for each patient: sex, age,
diabetes mellitus, chronic obstructive pulmonary disease (COPD),
ischemic heart disease, site of infection, microorganism responsi-
ble, bloodstream infection, antimicrobial treatment, pressure of
arterial oxygen/fraction of inspired oxygen (PaO2/FIO2), creat-
inine, bilirubin, leukocytes, lactic acid, platelets, international
normalized ratio (INR), activated partial thromboplastin time
(aPTT), Sepsis-related Organ Failure Assessment [SOFA] score
[25] and Acute Physiology and Chronic Health Evaluation
(APACHE)-II score [26]. We assessed survival at 30 days as the
endpoint.
Proteolytic, inflammatory and prothrombotic marker
assays
Blood samples were collected at days 1, 4 and 8 of ICU
admission. Serum separator tubes were used to determine MMP-
9, TIMP-1, TNF-alpha and IL-10 concentrations, and venous
citrated plasma tubes to determine PAI-1 concentration. Venous
Figure 1. Serum MMP-9, TIMP-1 and TIMP-1/MMP-9 ratio in survivor and non-survivor septic patient showed as median
(percentiles 25–75). MMP = Matrix metalloproteinase; TIMP = Tissue inhibitor of matrix metalloproteinase.
doi:10.1371/journal.pone.0094318.g001
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blood samples were taken and centrifuged within 30 minutes at
1000 g for 15 min, and frozen at 280uC until assayed.
The assay of MMP-9 and TIMP-1 was centralized in
Atherosclerosis Research Laboratory of CIMA-University of
Navarra (Pamplona, Spain). Specific ELISA (Quantikine, R&D
Figure 2. Serum TNF-alpha and IL-10 levels and plasma PAI-1 levels in survivor and non-survivor septic patients showed as median
(percentile 25–75). TNF = tumour necrosis factor; IL = Interleukin; PAI = Plasminogen activator inhibitor.
doi:10.1371/journal.pone.0094318.g002
Table 2. Logistic regression analyses to predict 30-day mortality.
Odds Ratio 95% Confidence Interval P
First model:
TIMP-1/MMP-9 ratio at day 1 1.11 1.011–1.223 0.03
SOFA score at day 1 1.17 1.083–1.268 ,0.001
Diabetes mellitus 1.99 1.137–3.489 0.02
Second model:
TIMP-1/MMP-9 ratio at day 4 1.27 1.004–1.617 0.047
SOFA score at day 4 1.15 1.050–1.267 0.003
Diabetes mellitus 2.76 1.182–6.425 0.02
Third model:
TIMP-1/MMP-9 ratio at day 8 1.76 1.041–2.977 0.03
SOFA score at day 8 1.19 1.064–1.334 0.002
Diabetes mellitus 1.93 0.652–5.721 0.23
TIMP = tissue inhibitor of matrix metalloproteinase; MMP = matrix metalloproteinase; SOFA = Sepsis-related Organ Failure Assessment score.
doi:10.1371/journal.pone.0094318.t002
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Systems, Abingdon, United Kingdom) was used according to
manufacturer’s instructions with a serum dilution of 1:80 and
1:100 respectively. The interassay coefficients of variation (CV)
were ,8% (n = 20) and the detection limits for the assays were
0.156 ng/ml and 0.08 ng/ml respectively.
Assays for TNF-alpha, IL-10 and PAI-1 were performed at the
Laboratory Department of the Hospital Universitario de Canarias
(La Laguna, Santa Cruz de Tenerife, Spain). TNF-alpha and IL-
10 were measured in serum by solid-phase chemiluminescent
immunometric assays (Immulite, Siemens Healthcare Diagnostics
Products, Llanberis, United Kingdom). The interassay CV were,
6.5% (n = 20) and ,9.9% (n = 40) respectively, and the detection
limits for the assays were 1.7 pg/ml and 1 pg/ml respectively.
PAI-1 antigen was assayed by specific ELISA (Imubind Plasma
PAI-1 ElisaTM, American Diagnostica, Inc, Stanford, CT, USA).
This assay detects latent (inactive) and active forms of PAI-1 and
PAI-1 complexes. The interassay CV was ,5% (n = 20) and the
detection limit for the assay was 1 ng/ml.
Statistical Methods
Continuous variables are reported as medians and interquartile
ranges. Categorical variables are reported as frequencies and
percentages. Comparisons of continuous variables between groups
were carried out using Wilcoxon, Mann-Whitney or Friedman
tests. Comparisons between groups for categorical variables were
carried out with chi-square test. Logistic regression analyses were
applied to determine the independent contribution of TIMP-1/
MMP-9 ratio at days 1, 4 and 8 on 30-day mortality, controlling
for SOFA score and diabetes mellitus. To avoid the collinearity
effect, we included only SOFA score and age as co-predictors.
Odds ratio (OR) and 95% confidence intervals (CI) were
calculated as measures of the clinical impact of the predictor
variables. We plotted receiver operating characteristic (ROC)
curves using survival at 30 days as the classification variable and
TIMP-1/MMP-9 ratio at days 1, 4 and 8 as prognostic variables.
The association between continuous variables was assessed using
Spearman’s rank correlation coefficient. A P value of less than 0.05
was considered statistically significant. Statistical analyses were
Figure 3. Receiver operation characteristic analyses using TIMP-1/MMP-9 ratio at day 1, 4 and 8 after admission as predictor of
mortality at 30 days in severe septic patients.
doi:10.1371/journal.pone.0094318.g003
Table 3. Correlations between circulating TIMP-1/MMP-9 ratio levels and TNF-alpha, IL-10, PAI-1, lactic acid, SOFA score, platelet,
INR and aPTT at days 1, 4 and 8.
Day 1 Day 4 Day 8
TNF-alpha rho = 0.45; p,0.001 rho = 0.20; p = 0.04 rho = 0.25; p = 0.01
IL-10 rho = 0.51; p,0.001 rho = 0.33; p,0.001 rho = 0.19; p = 0.05
PAI-1 rho = 0.36; p,0.001 rho = 0.34; p,0.001 rho = 0.23; p = 0.01
Lactic acid rho = 0.45; p,0.001 rho = 0.31; p,0.001 rho = 0.21; p = 0.02
SOFA score rho = 0.51; p,0.001 rho = 0.31; p,0.001 rho = 0.36; p,0.001
Platelet rho = 20.46; p,0.001 rho = 20.34; p,0.001 rho = 20.26; p = 0.004
INR rho = 0.49; p,0.001 rho = 0.23; p = 0.01 rho = 0.11; p = 0.26
aPTT rho = 0.34; p,0.001 rho = 0.22; p = 0.01 rho = 0.08; p = 0.41
Age rho = 0.12; p = 0.02 rho = 0.19; p = 0.01 rho = 0.25; p = 0.003
TIMP = tissue inhibitor of matrix metalloproteinase; MMP = matrix metalloproteinase; TNF = tumour necrosis factor; IL = Interleukin; PAI = plasminogen activator
inhibitor; SOFA = Sepsis-related Organ Failure Assessment score; INR = international normalized ratio; aPTT = activated partial thromboplastin time.
doi:10.1371/journal.pone.0094318.t003
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performed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and
NCSS 2000 (Kaysville, Utah).
Results
Comparison of demographic and clinical parameters between
non-surviving (n = 98) and surviving septic patients (n = 197) is
shown in Table 1. Non-survivors were older and showed higher
diabetes mellitus, creatinine, lactic acid, INR, aPTT, SOFA and
APACHE-II, and lower platelet count than survivors. No
differences were observed regarding sex, COPD, ischemic heart
disease, site of infection, microorganism responsible, bloodstream
infection and antimicrobial treatment.
Non-surviving septic patients showed higher serum TIMP-1
levels, lower serum MMP-9 levels and higher TIMP-1/MMP-9
ratio than survivors at days 1, 4 and 8 (Table 1, Figure 1).
Additionally, non-surviving septic patients exhibited higher PAI-1
and IL- 10 levels at days 1, 4 and 8, and higher TNF-alpha at day
4 and 8 than survivors (Table 1 and Figure 2).
Logistic regression analysis showed that TIMP-1/MMP-9 ratios
at day 1 (OR = 1.11; 95% CI = 1.011–1.223; p = 0.03), day 4
(OR = 1.27; 95% CI = 1.004–1.617; p = 0.047) and day 8
(OR = 1.76; 95% CI = 1.041–2.977; p = 0.03) were associated
with higher mortality at 30 days, controlling for SOFA score
(Table 2).
On ROC curve analysis, the area under the curve of TIMP-1/
MMP-9 ratios at day 1, 4 and 8 to predict 30-day survival were
0.66 (95% CI = 0.60–0.72; p,0.001), 0.67 (95% CI = 0.59–0.74;
p = 0.001) and 0.69 (95% CI = 0.60–0.77; p = 0.005) respectively,
(Figure 3).
As shown in Table 3, TIMP-1/MMP-9 ratios at days 1, 4 and 8
correlated with circulating TNF-alpha, IL-10, PAI-1 and lactic
acid levels, SOFA score, and platelet count, and at days 1 and 4
with INR and aPTT.
Discussion
A novel finding of our study was that non-surviving septic
patients showed persistently higher circulating levels TIMP-1
levels, lower circulating MMP-9 levels and higher TIMP-1/MMP-
9 ratio than survivors during the first week of ICU stay. In
addition, we found for the first time that the TIMP-1/MMP-9
ratio during the first week was associated with mortality according
to the results of logistic regression analyses. Two previous studies
exploring MMP levels during the course of sepsis found no
significant differences between surviving and non-surviving
patients regarding TIMP-1 [21] and MMP-9 levels [21,22]. The
higher sample size of our study (295 patients) compared with the
smaller size (20 and 44 patients respectively) of previous studies
[21,22] could explain the significant differences reported between
surviving and non- surviving patients.
In a previous study by our team we found that TIMP-1 levels at
the time of severe sepsis diagnosis could be used as a biomarker of
sepsis outcome [19]. A novel finding of the current study was that
TIMP-1/MMP-9 ratio during the first week could be used as a
biomarker of sepsis outcome according to the results of ROC
curve analysis. In addition, we previously reported that circulating
TIMP-1 levels were associated with TNF-alpha, IL-10, PAI-1,
SOFA score, lactic acid levels, platelet count, aPTT and INR [19].
Another novel finding of the present study was a significant
association between TIMP-1/MMP-9 ratio and circulating
cytokine levels, coagulation parameters and SOFA score during
the first week.
Taken together, these results indicate that TIMP-1 and MMP-9
levels could play a pathophysiological role in septic patients.
MMP-9 inhibits platelet aggregation [27,28] and an association
between circulating TIMP-1 and PAI-1 levels has been found
[29,30]. In addition, an association between PAI-1 levels and
sepsis mortality has been reported [31–33]. Thus, it may be that
the higher circulating levels TIMP-1 levels, lower circulating
MMP-9 levels and higher TIMP-1/MMP-9 ratio found in non-
surviving patients during the first week could favour a prothrom-
botic state and contribute to capillary thrombosis, multiple organ
dysfunction, and death in septic patients.
From a therapeutic perspective, the development of modulators
of MMP/TIMP activity could be used as a new class of drugs for
the treatment of severe sepsis [34,35].
The strengths of our study were the large sample size and the
follow-up of circulating TIMP-1, MMP-9, TNF-alpha, IL-10, and
PAI-1 levels throughout the first week after diagnosis of severe
sepsis. However, our study has certain limitations. First, we did not
analyze other MMPs and TIMPs; and it could be interesting to
describe levels of other MMPs and TIMPs, and the ratios between
them. Second, measurement of other cytokines and coagulation
markers would be desirable in order to better evaluate the
relationship between proteolysis, inflammation and coagulation in
these patients. Third, we analyzed serum levels of MMP-9 and
TIMP-1 but plasma determination is preferable because there
could be a release of several MMPs or TIMPs from platelets in
serum [36–39].
In conclusion, the novel findings of our study were that non-
surviving septic patients showed persistently higher TIMP-1/
MMP-9 ratio than survivors during the first week, which was
associated with severity, coagulation state, circulating cytokine
levels and mortality, thus representing a new biomarker of sepsis
outcome.
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